Key result
Urinary [TIMP-2]*[IGFBP7] measured on day one after TAVI accurately predicted acute kidney injury stage 2 or 3 with an AUC of 0.971, 100% sensitivity, and 90% specificity.
Why the study?
Do urinary G1 cell cycle arrest biomarkers (TIMP-2 and IGFBP7) predict the occurrence of acute kidney injury stage 2/3 in patients undergoing TAVI?
Observational (n=40)
Double-blind
No
Do urinary G1 cell cycle arrest biomarkers (TIMP-2 and IGFBP7) predict the occurrence of acute kidney injury stage 2/3 in patients undergoing TAVI?
Effect estimate: AUC 0.971 (95% CI 0.914-1.000)
p-value: p=0.001
Early elevation of urinary TIMP-2 and IGFBP7 provides excellent diagnostic accuracy for predicting severe AKI after TAVI, outperforming traditional markers like serum creatinine.
May aid early post-TAVI AKI risk stratification; leaves open validation before clinical adoption.
BACKGROUND: Acute kidney injury (AKI) is a common complication following transcatheter aortic valve implantation (TAVI) leading to increased mortality and morbidity. Urinary G1 cell cycle arrest proteins TIMP-2 and IGFBP7 have recently been suggested as sensitive biomarkers for early detection of AKI in critically ill patients. However, the precise role of urinary TIMP-2 and IGFBP7 in patients undergoing TAVI is unknown. METHODS: In a prospective observational trial, 40 patients undergoing TAVI (either transaortic or transapical) were enrolled. Serial measurements of TIMP-2 and IGFBP7 were performed in the early post interventional course. The primary clinical endpoint was the occurrence of AKI stage 2/3 according to the KDIGO classification. RESULTS: Now we show, that ROC analyses of [TIMP-2]*[IGFBP7] on day one after TAVI reveals a sensitivity of 100 % and a specificity of 90 % for predicting AKI 2/3 (AUC 0.971, 95 % CI 0.914-1.0, SE 0.0299, p = 0.001, cut-off 1.03). In contrast, preoperative and postoperative serum creatinine levels as well as glomerular filtration rate (GFR) and perioperative change in GFR did not show any association with the development of AKI. Furthermore, [TIMP-2]*[IGFBP7] remained stable in patients with AKI ≤1, but its levels increased significantly as early as 24 h after TAVI in patients who developed AKI 2/3 in the further course (4.77 ± 3.21 vs. 0.48 ± 0.68, p = 0.022). Mean patients age was 81.2 ± 5.6 years, 16 patients were male (40.0 %). 35 patients underwent transapical and five patients transaortic TAVI. 15 patients (37.5 %) developed any kind of AKI; eight patients (20 %) met the primary endpoint and seven patients required renal replacement therapy (RRT) within 72 h after surgery. CONCLUSION: Early elevation of urinary cell cycle arrest biomarkers after TAVI is associated with the development of postoperative AKI. [TIMP-2]*[IGFBP7] provides an excellent diagnostic accuracy in the prediction of AKI that is superior to that of serum creatinine.
No takes yet. Share an insight, caveat, or question.
Dusse et al. (2015) conducted an observational in Severe symptomatic aortic stenosis (n=40). Urinary [TIMP-2]*[IGFBP7] biomarker vs. Serum creatinine was evaluated on Occurrence of acute kidney injury (AKI) stage 2 or 3 according to KDIGO classification within 48 hours after surgery (AUC 0.971, 95% CI 0.914-1.000, p=0.001). Urinary [TIMP-2]*[IGFBP7] measured on day one after TAVI accurately predicted acute kidney injury stage 2 or 3 with an AUC of 0.971, 100% sensitivity, and 90% specificity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: